T21	dis 43 65	acute myeloid leukemia
T1	Token 0 10	Monoclonal
T2	Token 11 21	antibodies
T3	Token 22 25	for
T4	Token 26 29	the
T5	Token 30 39	treatment
T6	Token 40 42	of
T7	Token 43 48	acute
T8	Token 49 56	myeloid
T9	Token 57 65	leukemia
T10	Token 65 66	.
R1	amod Arg1:T2 Arg2:T1
R2	det Arg1:T5 Arg2:T4
R3	prep_for Arg1:T2 Arg2:T5
R4	amod Arg1:T9 Arg2:T7
R5	amod Arg1:T9 Arg2:T8
R6	prep_of Arg1:T5 Arg2:T9
R7	punct Arg1:T2 Arg2:T10
T66	dis 92 114	acute myeloid leukemia
T67	dis 116 119	AML
T22	Token 67 76	Currently
T23	Token 76 77	,
T24	Token 78 86	patients
T25	Token 87 91	with
T26	Token 92 97	acute
T27	Token 98 105	myeloid
T28	Token 106 114	leukemia
T29	Token 115 116	(
T30	Token 116 119	AML
T31	Token 119 120	)
T32	Token 121 124	are
T33	Token 125 132	treated
T34	Token 133 137	with
T35	Token 138 147	cytotoxic
T36	Token 148 160	chemotherapy
T37	Token 161 164	and
T38	Token 165 178	hematopoietic
T39	Token 179 183	stem
T40	Token 184 188	cell
T41	Token 189 204	transplantation
T42	Token 205 206	(
T43	Token 206 210	HSCT
T44	Token 210 211	)
T45	Token 211 212	.
R8	advmod Arg1:T33 Arg2:T22
R9	punct Arg1:T33 Arg2:T23
R10	nsubjpass Arg1:T33 Arg2:T24
R11	amod Arg1:T28 Arg2:T26
R12	amod Arg1:T28 Arg2:T27
R13	prep_with Arg1:T24 Arg2:T28
R14	punct Arg1:T30 Arg2:T29
R15	abbrev Arg1:T28 Arg2:T30
R16	punct Arg1:T30 Arg2:T31
R17	auxpass Arg1:T33 Arg2:T32
R18	amod Arg1:T36 Arg2:T35
R19	prep_with Arg1:T33 Arg2:T36
R20	amod Arg1:T41 Arg2:T38
R21	nn Arg1:T41 Arg2:T39
R22	nn Arg1:T41 Arg2:T40
R23	prep_with Arg1:T33 Arg2:T41
R24	conj_and Arg1:T36 Arg2:T41
R25	punct Arg1:T43 Arg2:T42
R26	abbrev Arg1:T41 Arg2:T43
R27	punct Arg1:T43 Arg2:T44
R28	punct Arg1:T33 Arg2:T45
T68	Token 213 217	With
T69	Token 218 222	this
T70	Token 223 231	approach
T71	Token 231 232	,
T72	Token 233 236	the
T73	Token 237 245	majority
T74	Token 246 248	of
T75	Token 249 257	patients
T76	Token 258 263	still
T77	Token 264 267	die
T78	Token 268 270	of
T79	Token 271 276	their
T80	Token 277 284	disease
T81	Token 285 292	because
T82	Token 293 295	of
T83	Token 296 300	both
T84	Token 301 318	treatment-related
T85	Token 319 328	mortality
T86	Token 329 332	and
T87	Token 333 340	relapse
T88	Token 340 341	.
R29	det Arg1:T70 Arg2:T69
R30	prep_with Arg1:T77 Arg2:T70
R31	punct Arg1:T77 Arg2:T71
R32	det Arg1:T73 Arg2:T72
R33	nsubj Arg1:T77 Arg2:T73
R34	prep_of Arg1:T73 Arg2:T75
R35	advmod Arg1:T77 Arg2:T76
R36	poss Arg1:T80 Arg2:T79
R37	prep_of Arg1:T77 Arg2:T80
R38	preconj Arg1:T85 Arg2:T83
R39	amod Arg1:T85 Arg2:T84
R40	prep_because_of Arg1:T77 Arg2:T85
R41	prep_because_of Arg1:T77 Arg2:T87
R42	conj_and Arg1:T85 Arg2:T87
R43	punct Arg1:T77 Arg2:T88
T106	Token 342 350	Recently
T107	Token 350 351	,
T108	Token 352 362	monoclonal
T109	Token 363 373	antibodies
T110	Token 374 377	and
T111	Token 378 394	immunoconjugates
T112	Token 395 399	have
T113	Token 400 404	been
T114	Token 405 414	developed
T115	Token 415 420	which
T116	Token 421 432	potentially
T117	Token 433 436	may
T118	Token 437 445	increase
T119	Token 446 449	the
T120	Token 450 458	efficacy
T121	Token 459 461	of
T122	Token 462 471	treatment
T123	Token 472 475	and
T124	Token 476 484	decrease
T125	Token 485 494	morbidity
T126	Token 495 498	and
T127	Token 499 508	mortality
T128	Token 509 511	by
T129	Token 512 524	specifically
T130	Token 525 534	targeting
T131	Token 535 538	the
T132	Token 539 548	malignant
T133	Token 549 553	cell
T134	Token 553 554	.
R44	advmod Arg1:T114 Arg2:T106
R45	punct Arg1:T114 Arg2:T107
R46	amod Arg1:T109 Arg2:T108
R47	nsubjpass Arg1:T114 Arg2:T109
R48	conj_and Arg1:T109 Arg2:T111
R49	nsubjpass Arg1:T114 Arg2:T111
R50	aux Arg1:T114 Arg2:T112
R51	auxpass Arg1:T114 Arg2:T113
R52	nsubj Arg1:T118 Arg2:T115
R53	nsubj Arg1:T124 Arg2:T115
R54	advmod Arg1:T118 Arg2:T116
R55	aux Arg1:T118 Arg2:T117
R56	ccomp Arg1:T114 Arg2:T118
R57	det Arg1:T120 Arg2:T119
R58	dobj Arg1:T118 Arg2:T120
R59	prep_of Arg1:T120 Arg2:T122
R60	ccomp Arg1:T114 Arg2:T124
R61	conj_and Arg1:T118 Arg2:T124
R62	dobj Arg1:T124 Arg2:T125
R63	dobj Arg1:T124 Arg2:T127
R64	conj_and Arg1:T125 Arg2:T127
R65	advmod Arg1:T130 Arg2:T129
R66	prepc_by Arg1:T124 Arg2:T130
R67	det Arg1:T133 Arg2:T131
R68	amod Arg1:T133 Arg2:T132
R69	dobj Arg1:T130 Arg2:T133
R70	punct Arg1:T114 Arg2:T134
T165	Token 555 567	Unconjugated
T166	Token 568 578	monoclonal
T167	Token 579 589	antibodies
T168	Token 590 594	have
T169	Token 595 600	shown
T170	Token 601 605	only
T171	Token 606 614	moderate
T172	Token 615 623	activity
T173	Token 623 624	.
R71	amod Arg1:T167 Arg2:T165
R72	amod Arg1:T167 Arg2:T166
R73	nsubj Arg1:T169 Arg2:T167
R74	aux Arg1:T169 Arg2:T168
R75	advmod Arg1:T171 Arg2:T170
R76	amod Arg1:T172 Arg2:T171
R77	dobj Arg1:T169 Arg2:T172
R78	punct Arg1:T169 Arg2:T173
T182	Token 625 626	A
T183	Token 627 633	second
T184	Token 633 634	,
T185	Token 635 639	more
T186	Token 640 649	effective
T187	Token 649 650	,
T188	Token 651 659	approach
T189	Token 660 668	involves
T190	Token 669 677	antibody
T191	Token 678 689	conjugation
T192	Token 690 694	with
T193	Token 695 706	radioactive
T194	Token 707 716	particles
T195	Token 717 719	or
T196	Token 720 736	chemotherapeutic
T197	Token 737 743	agents
T198	Token 743 744	,
T199	Token 745 749	such
T200	Token 750 752	as
T201	Token 752 753	,
T202	Token 754 766	immunotoxins
T203	Token 766 767	,
T204	Token 768 776	targeted
T205	Token 777 785	delivery
T206	Token 786 788	of
T207	Token 789 793	cell
T208	Token 794 801	killing
T209	Token 801 802	.
R79	det Arg1:T188 Arg2:T182
R80	amod Arg1:T188 Arg2:T183
R81	punct Arg1:T183 Arg2:T184
R82	advmod Arg1:T186 Arg2:T185
R83	dep Arg1:T183 Arg2:T186
R84	punct Arg1:T188 Arg2:T187
R85	nsubj Arg1:T189 Arg2:T188
R86	nn Arg1:T191 Arg2:T190
R87	dobj Arg1:T189 Arg2:T191
R88	amod Arg1:T194 Arg2:T193
R89	prep_with Arg1:T191 Arg2:T194
R90	amod Arg1:T197 Arg2:T196
R91	prep_with Arg1:T191 Arg2:T197
R92	conj_or Arg1:T194 Arg2:T197
R93	punct Arg1:T197 Arg2:T198
R94	punct Arg1:T202 Arg2:T201
R95	prep_such_as Arg1:T197 Arg2:T202
R96	punct Arg1:T202 Arg2:T203
R97	amod Arg1:T205 Arg2:T204
R98	appos Arg1:T202 Arg2:T205
R99	nn Arg1:T208 Arg2:T207
R100	prep_of Arg1:T205 Arg2:T208
R101	punct Arg1:T189 Arg2:T209
T271	ggp 816 820	CD33
T272	ggp 822 826	CD45
T273	ggp 832 836	CD66
T232	Token 803 806	The
T233	Token 807 815	antigens
T234	Token 816 820	CD33
T235	Token 820 821	,
T236	Token 822 826	CD45
T237	Token 826 827	,
T238	Token 828 831	and
T239	Token 832 836	CD66
T240	Token 836 837	,
T241	Token 838 841	are
T242	Token 842 847	three
T243	Token 848 856	antigens
T244	Token 857 859	to
T245	Token 860 865	which
T246	Token 866 876	monoclonal
T247	Token 877 887	antibodies
T248	Token 888 892	have
T249	Token 893 897	been
T250	Token 898 906	directed
T251	Token 906 907	.
R102	det Arg1:T233 Arg2:T232
R103	nsubj Arg1:T243 Arg2:T233
R104	dep Arg1:T233 Arg2:T234
R105	punct Arg1:T234 Arg2:T235
R106	dep Arg1:T233 Arg2:T236
R107	conj_and Arg1:T234 Arg2:T236
R108	punct Arg1:T234 Arg2:T237
R109	dep Arg1:T233 Arg2:T239
R110	conj_and Arg1:T234 Arg2:T239
R111	punct Arg1:T234 Arg2:T240
R112	cop Arg1:T243 Arg2:T241
R113	num Arg1:T243 Arg2:T242
R114	rel Arg1:T250 Arg2:T245
R115	amod Arg1:T247 Arg2:T246
R116	nsubjpass Arg1:T250 Arg2:T247
R117	aux Arg1:T250 Arg2:T248
R118	auxpass Arg1:T250 Arg2:T249
R119	rcmod Arg1:T243 Arg2:T250
R120	punct Arg1:T243 Arg2:T251
T329	che 949 959	ozogamicin
T330	che 1071 1084	calicheamicin
T331	ggp 1005 1023	anti-CD33 antibody
T274	Token 908 912	Most
T275	Token 913 923	experience
T276	Token 924 927	has
T277	Token 928 932	been
T278	Token 933 937	with
T279	Token 938 948	gemtuzumab
T280	Token 949 959	ozogamicin
T281	Token 960 961	(
T282	Token 961 969	Mylotarg
T283	Token 969 970	)
T284	Token 971 976	which
T285	Token 977 979	is
T286	Token 980 982	an
T287	Token 983 998	immunoconjugate
T288	Token 999 1001	of
T289	Token 1002 1004	an
T290	Token 1005 1014	anti-CD33
T291	Token 1015 1023	antibody
T292	Token 1024 1034	chemically
T293	Token 1035 1041	linked
T294	Token 1042 1044	to
T295	Token 1045 1046	a
T296	Token 1047 1053	potent
T297	Token 1054 1063	cytotoxic
T298	Token 1064 1069	agent
T299	Token 1069 1070	,
T300	Token 1071 1084	calicheamicin
T301	Token 1084 1085	.
R121	nsubj Arg1:T277 Arg2:T274
R122	dep Arg1:T274 Arg2:T275
R123	aux Arg1:T277 Arg2:T276
R124	nn Arg1:T280 Arg2:T279
R125	prep_with Arg1:T277 Arg2:T280
R126	nsubj Arg1:T287 Arg2:T280
R127	punct Arg1:T282 Arg2:T281
R128	appos Arg1:T280 Arg2:T282
R129	punct Arg1:T282 Arg2:T283
R130	cop Arg1:T287 Arg2:T285
R131	det Arg1:T287 Arg2:T286
R132	rcmod Arg1:T280 Arg2:T287
R133	det Arg1:T291 Arg2:T289
R134	amod Arg1:T291 Arg2:T290
R135	prep_of Arg1:T287 Arg2:T291
R136	advmod Arg1:T293 Arg2:T292
R137	partmod Arg1:T291 Arg2:T293
R138	det Arg1:T298 Arg2:T295
R139	amod Arg1:T298 Arg2:T296
R140	amod Arg1:T298 Arg2:T297
R141	prep_to Arg1:T293 Arg2:T298
R142	punct Arg1:T298 Arg2:T299
R143	appos Arg1:T298 Arg2:T300
R144	punct Arg1:T277 Arg2:T301
T385	che 1097 1107	ozogamicin
T386	dis 1159 1187	acute promyelocytic leukemia
T387	ggp 1236 1248	CD33 antigen
T332	Token 1086 1096	Gemtuzumab
T333	Token 1097 1107	ozogamicin
T334	Token 1108 1115	appears
T335	Token 1116 1118	to
T336	Token 1119 1121	be
T337	Token 1122 1134	particularly
T338	Token 1135 1141	active
T339	Token 1142 1144	in
T340	Token 1145 1153	patients
T341	Token 1154 1158	with
T342	Token 1159 1164	acute
T343	Token 1165 1178	promyelocytic
T344	Token 1179 1187	leukemia
T345	Token 1187 1188	,
T346	Token 1189 1197	possibly
T347	Token 1198 1205	related
T348	Token 1206 1208	to
T349	Token 1209 1212	the
T350	Token 1213 1217	high
T351	Token 1218 1228	expression
T352	Token 1229 1231	of
T353	Token 1232 1235	the
T354	Token 1236 1240	CD33
T355	Token 1241 1248	antigen
T356	Token 1249 1251	on
T357	Token 1252 1255	the
T358	Token 1256 1260	cell
T359	Token 1261 1268	surface
T360	Token 1268 1269	.
R145	nn Arg1:T333 Arg2:T332
R146	nsubj Arg1:T334 Arg2:T333
R147	xsubj Arg1:T338 Arg2:T333
R148	aux Arg1:T338 Arg2:T335
R149	cop Arg1:T338 Arg2:T336
R150	advmod Arg1:T338 Arg2:T337
R151	xcomp Arg1:T334 Arg2:T338
R152	prep_in Arg1:T338 Arg2:T340
R153	amod Arg1:T344 Arg2:T342
R154	amod Arg1:T344 Arg2:T343
R155	prep_with Arg1:T340 Arg2:T344
R156	punct Arg1:T344 Arg2:T345
R157	advmod Arg1:T347 Arg2:T346
R158	amod Arg1:T344 Arg2:T347
R159	det Arg1:T351 Arg2:T349
R160	amod Arg1:T351 Arg2:T350
R161	prep_to Arg1:T347 Arg2:T351
R162	det Arg1:T355 Arg2:T353
R163	nn Arg1:T355 Arg2:T354
R164	prep_of Arg1:T351 Arg2:T355
R165	det Arg1:T359 Arg2:T357
R166	nn Arg1:T359 Arg2:T358
R167	prep_on Arg1:T351 Arg2:T359
R168	punct Arg1:T334 Arg2:T360
T438	che 1290 1300	ozogamicin
T439	ggp 1279 1300	gemtuzumab ozogamicin
T388	Token 1270 1278	Although
T389	Token 1279 1289	gemtuzumab
T390	Token 1290 1300	ozogamicin
T391	Token 1301 1304	has
T392	Token 1305 1313	activity
T393	Token 1314 1316	as
T394	Token 1317 1318	a
T395	Token 1319 1325	single
T396	Token 1326 1331	agent
T397	Token 1331 1332	,
T398	Token 1333 1336	the
T399	Token 1337 1341	most
T400	Token 1342 1351	promising
T401	Token 1352 1358	result
T402	Token 1359 1362	may
T403	Token 1363 1365	be
T404	Token 1366 1370	seen
T405	Token 1371 1375	when
T406	Token 1376 1380	this
T407	Token 1381 1386	agent
T408	Token 1387 1389	is
T409	Token 1390 1398	combined
T410	Token 1399 1403	with
T411	Token 1404 1416	conventional
T412	Token 1417 1426	cytotoxic
T413	Token 1427 1439	chemotherapy
T414	Token 1439 1440	.
R169	mark Arg1:T391 Arg2:T388
R170	nn Arg1:T390 Arg2:T389
R171	nsubj Arg1:T391 Arg2:T390
R172	advcl Arg1:T404 Arg2:T391
R173	dobj Arg1:T391 Arg2:T392
R174	det Arg1:T396 Arg2:T394
R175	amod Arg1:T396 Arg2:T395
R176	prep_as Arg1:T391 Arg2:T396
R177	punct Arg1:T404 Arg2:T397
R178	det Arg1:T401 Arg2:T398
R179	advmod Arg1:T400 Arg2:T399
R180	amod Arg1:T401 Arg2:T400
R181	nsubjpass Arg1:T404 Arg2:T401
R182	aux Arg1:T404 Arg2:T402
R183	auxpass Arg1:T404 Arg2:T403
R184	advmod Arg1:T409 Arg2:T405
R185	det Arg1:T407 Arg2:T406
R186	nsubjpass Arg1:T409 Arg2:T407
R187	auxpass Arg1:T409 Arg2:T408
R188	advcl Arg1:T404 Arg2:T409
R189	amod Arg1:T413 Arg2:T411
R190	amod Arg1:T413 Arg2:T412
R191	prep_with Arg1:T409 Arg2:T413
R192	punct Arg1:T404 Arg2:T414
T440	Token 1441 1452	Preliminary
T441	Token 1453 1460	studies
T442	Token 1461 1465	have
T443	Token 1466 1475	suggested
T444	Token 1476 1477	a
T445	Token 1478 1482	high
T446	Token 1483 1491	complete
T447	Token 1492 1501	remission
T448	Token 1502 1506	rate
T449	Token 1507 1510	and
T450	Token 1511 1521	randomized
T451	Token 1522 1530	clinical
T452	Token 1531 1537	trials
T453	Token 1538 1541	are
T454	Token 1542 1550	underway
T455	Token 1550 1551	.
R193	amod Arg1:T441 Arg2:T440
R194	nsubj Arg1:T443 Arg2:T441
R195	aux Arg1:T443 Arg2:T442
R196	det Arg1:T448 Arg2:T444
R197	amod Arg1:T448 Arg2:T445
R198	amod Arg1:T448 Arg2:T446
R199	nn Arg1:T448 Arg2:T447
R200	dobj Arg1:T443 Arg2:T448
R201	amod Arg1:T452 Arg2:T450
R202	amod Arg1:T452 Arg2:T451
R203	nsubj Arg1:T454 Arg2:T452
R204	cop Arg1:T454 Arg2:T453
R205	conj_and Arg1:T443 Arg2:T454
R206	punct Arg1:T443 Arg2:T455
T521	dis 1608 1629	venoocclusive disease
T522	dis 1633 1664	sinusoidal obstructive syndrome
T468	Token 1552 1553	A
T469	Token 1554 1560	unique
T470	Token 1561 1570	potential
T471	Token 1571 1579	toxicity
T472	Token 1580 1583	has
T473	Token 1584 1588	been
T474	Token 1589 1599	identified
T475	Token 1599 1600	,
T476	Token 1601 1607	namely
T477	Token 1608 1621	venoocclusive
T478	Token 1622 1629	disease
T479	Token 1630 1632	or
T480	Token 1633 1643	sinusoidal
T481	Token 1644 1655	obstructive
T482	Token 1656 1664	syndrome
T483	Token 1665 1670	which
T484	Token 1671 1674	may
T485	Token 1675 1677	be
T486	Token 1678 1689	problematic
T487	Token 1690 1695	among
T488	Token 1696 1704	patients
T489	Token 1705 1708	who
T490	Token 1709 1721	subsequently
T491	Token 1722 1729	undergo
T492	Token 1730 1734	HSCT
T493	Token 1734 1735	.
R207	det Arg1:T471 Arg2:T468
R208	amod Arg1:T471 Arg2:T469
R209	amod Arg1:T471 Arg2:T470
R210	nsubjpass Arg1:T474 Arg2:T471
R211	aux Arg1:T474 Arg2:T472
R212	auxpass Arg1:T474 Arg2:T473
R213	punct Arg1:T474 Arg2:T475
R214	prep Arg1:T474 Arg2:T476
R215	amod Arg1:T478 Arg2:T477
R216	pobj Arg1:T476 Arg2:T478
R217	nsubj Arg1:T486 Arg2:T478
R218	amod Arg1:T482 Arg2:T480
R219	amod Arg1:T482 Arg2:T481
R220	pobj Arg1:T476 Arg2:T482
R221	conj_or Arg1:T478 Arg2:T482
R222	nsubj Arg1:T486 Arg2:T482
R223	aux Arg1:T486 Arg2:T484
R224	cop Arg1:T486 Arg2:T485
R225	rcmod Arg1:T478 Arg2:T486
R226	prep_among Arg1:T486 Arg2:T488
R227	nsubj Arg1:T491 Arg2:T488
R228	advmod Arg1:T491 Arg2:T490
R229	rcmod Arg1:T488 Arg2:T491
R230	dobj Arg1:T491 Arg2:T492
R231	punct Arg1:T474 Arg2:T493
T523	Token 1736 1738	An
T524	Token 1739 1749	additional
T525	Token 1750 1758	strategy
T526	Token 1759 1767	includes
T527	Token 1768 1780	radiolabeled
T528	Token 1781 1791	monoclonal
T529	Token 1792 1802	antibodies
T530	Token 1803 1805	to
T531	Token 1806 1815	intensify
T532	Token 1816 1819	the
T533	Token 1820 1832	conditioning
T534	Token 1833 1840	regimen
T535	Token 1841 1846	prior
T536	Token 1847 1849	to
T537	Token 1850 1854	HSCT
T538	Token 1854 1855	.
R232	det Arg1:T525 Arg2:T523
R233	amod Arg1:T525 Arg2:T524
R234	nsubj Arg1:T526 Arg2:T525
R235	amod Arg1:T529 Arg2:T527
R236	amod Arg1:T529 Arg2:T528
R237	dobj Arg1:T526 Arg2:T529
R238	aux Arg1:T531 Arg2:T530
R239	xcomp Arg1:T526 Arg2:T531
R240	det Arg1:T534 Arg2:T532
R241	amod Arg1:T534 Arg2:T533
R242	dobj Arg1:T531 Arg2:T534
R243	prep_prior_to Arg1:T534 Arg2:T537
R244	punct Arg1:T526 Arg2:T538
T574	org 1925 1929	CD45
T575	ggp 1920 1940	anti-CD45 antibodies
T553	Token 1856 1859	The
T554	Token 1860 1864	most
T555	Token 1865 1874	promising
T556	Token 1875 1882	results
T557	Token 1883 1887	have
T558	Token 1888 1892	been
T559	Token 1893 1901	obtained
T560	Token 1902 1906	with
T561	Token 1907 1919	radiolabeled
T562	Token 1920 1929	anti-CD45
T563	Token 1930 1940	antibodies
T564	Token 1940 1941	.
R245	det Arg1:T556 Arg2:T553
R246	amod Arg1:T556 Arg2:T554
R247	amod Arg1:T556 Arg2:T555
R248	nsubjpass Arg1:T559 Arg2:T556
R249	aux Arg1:T559 Arg2:T557
R250	auxpass Arg1:T559 Arg2:T558
R251	amod Arg1:T563 Arg2:T561
R252	amod Arg1:T563 Arg2:T562
R253	prep_with Arg1:T559 Arg2:T563
R254	punct Arg1:T559 Arg2:T564
